Gene expression data from whole blood of a Phase II randomized clinical trial of the treatment of methamphetamine dependence with topiramate. Gene expression data from whole blood of a Phase II randomized clinical trial of the treatment of methamphetamine dependence with topiramate

A genome-wide RNA expression study based on a Phase II randomized placebo-controlled clinical trial of topiramate (TPM) treatment of methamphetamine (METH) dependence. Gene expression data were analyzed based on TPM responses at Weeks 8 and 12, to identify differentially expressed genes and related pathways. Overall design: From a previously conducted randomized, Phase II double-blind, multi-center, placebo-controlled clinical trial of treatment of METH dependence with TPM (Elkashef et al., Addiction. 2012, PMID: 22221594), 99 gave consent to participate in a genome-wide expression study were included in this report. The total RNA was collected from whole blood for each of the 50 TPM- and 49 placebo-treated participants at three time points: baseline, week 8, and week 12, respectively. Gene expression data of a total of 209 Affymetrix Human Genome U-133 Plus 2.0 chips passed quality control from 50 TPM- and 48 placebo-treated participants at baseline (88 chips), Week 8 (65 chips), and Week 12 (56 chips). Gene expression data were analyzed based on METH-dependent participants’ TPM responses at Weeks 8 and 12, to identify differentially expressed genes and related pathways that could be related to differential TPM responses among METH-dependent study participants.

本研究是一项基于托吡酯（topiramate, TPM）治疗甲基苯丙胺（methamphetamine, METH）依赖的II期随机安慰剂对照临床试验（Phase II randomized placebo-controlled clinical trial）的全基因组RNA表达研究（genome-wide RNA expression study），旨在基于第8周和第12周的托吡酯应答情况分析基因表达数据，筛选差异表达基因（differentially expressed genes）及其相关通路。
总实验设计：本研究的数据来源于一项已完成的托吡酯治疗甲基苯丙胺依赖的随机双盲多中心II期安慰剂对照临床试验（Elkashef等, Addiction. 2012, PMID: 22221594），本报告纳入了其中同意参与全基因组表达研究的99名受试者。研究分别在基线、第8周和第12周三个时间点，从50名接受托吡酯治疗及49名接受安慰剂治疗的受试者的全血中提取总RNA。最终共有209份通过质量控制的基因表达芯片数据，所用芯片为Affymetrix Human Genome U-133 Plus 2.0芯片，来自50名托吡酯治疗受试者与48名安慰剂治疗受试者，各时间点的芯片数分别为：基线88份、第8周65份、第12周56份。本研究基于第8周和第12周的甲基苯丙胺依赖受试者的托吡酯应答情况分析基因表达数据，以筛选与甲基苯丙胺依赖受试者托吡酯应答差异相关的差异表达基因及其相关通路。